Christine J. Saoud

Array ( [id] => 20415088 [patent_doc_number] => 12498366 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-16 [patent_title] => Measurement method for fibroblast growth factor-23 by forming immunocomplexes [patent_app_type] => utility [patent_app_number] => 16/616778 [patent_app_country] => US [patent_app_date] => 2018-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5575 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 206 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16321297 [patent_doc_number] => 10781253 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-22 [patent_title] => LEAP2 binding agents and compositions thereof [patent_app_type] => utility [patent_app_number] => 15/987766 [patent_app_country] => US [patent_app_date] => 2018-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 25 [patent_no_of_words] => 34748 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 178 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15987766 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14700145 [patent_doc_number] => 10377806 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-13 [patent_title] => Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof [patent_app_type] => utility [patent_app_number] => 15/979881 [patent_app_country] => US [patent_app_date] => 2018-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 81 [patent_figures_cnt] => 144 [patent_no_of_words] => 78863 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15979881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13982491 [patent_doc_number] => 20190060403 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => USES AND METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES [patent_app_type] => utility [patent_app_number] => 15/959054 [patent_app_country] => US [patent_app_date] => 2018-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30822 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15959054 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15963159 [patent_doc_number] => 20200165331 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => VNAR HAVING ANTI-ANGIOGENIC ACTIVITY IN SOLID TUMOURS OF PET ANIMALS [patent_app_type] => utility [patent_app_number] => 16/606908 [patent_app_country] => US [patent_app_date] => 2018-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3912 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16606908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18604684 [patent_doc_number] => 11746134 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-05 [patent_title] => Human FGF21 mutant with improved effectiveness and stability and pharmaceutical composition thereof [patent_app_type] => utility [patent_app_number] => 16/608706 [patent_app_country] => US [patent_app_date] => 2018-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 11 [patent_no_of_words] => 4198 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16608706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16275583 [patent_doc_number] => 10758590 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-01 [patent_title] => Methods of using compositions comprising variants and fusions of FGF 19 polypeptides for treating diabetes [patent_app_type] => utility [patent_app_number] => 15/950050 [patent_app_country] => US [patent_app_date] => 2018-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 40 [patent_no_of_words] => 31329 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 386 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15950050 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13360061 [patent_doc_number] => 20180231570 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => IGFBP7 FOR PREDICTION OF RISK OF AKI WHEN MEASURED PRIOR TO SURGERY [patent_app_type] => utility [patent_app_number] => 15/943104 [patent_app_country] => US [patent_app_date] => 2018-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16971 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15943104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16572179 [patent_doc_number] => 10894090 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-19 [patent_title] => Antibody drug conjugates (ADC) that bind to 191P4D12 proteins [patent_app_type] => utility [patent_app_number] => 15/943527 [patent_app_country] => US [patent_app_date] => 2018-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 55 [patent_no_of_words] => 35297 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15943527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16139069 [patent_doc_number] => 10702588 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-07 [patent_title] => Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain [patent_app_type] => utility [patent_app_number] => 15/941033 [patent_app_country] => US [patent_app_date] => 2018-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 43 [patent_no_of_words] => 94877 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15941033 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13576959 [patent_doc_number] => 20180340028 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-29 [patent_title] => METHODS FOR THE TREATMENT OF EPILEPSY [patent_app_type] => utility [patent_app_number] => 15/926149 [patent_app_country] => US [patent_app_date] => 2018-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4638 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15926149 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17563173 [patent_doc_number] => 20220127322 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => DUAL-TARGET FUSION PROTEINS COMPRISING THE FC PORTION OF AN IMMUNOGLOBULIN [patent_app_type] => utility [patent_app_number] => 16/485153 [patent_app_country] => US [patent_app_date] => 2018-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10559 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16485153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15432453 [patent_doc_number] => 20200030409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => LYPD1 INHIBITOR AND METHOD FOR PRODUCING BIOLOGICAL TISSUE USING SAME [patent_app_type] => utility [patent_app_number] => 16/491498 [patent_app_country] => US [patent_app_date] => 2018-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13685 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16491498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17874388 [patent_doc_number] => 11446381 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-20 [patent_title] => Stable aqueous formulation for growth hormone [patent_app_type] => utility [patent_app_number] => 15/913550 [patent_app_country] => US [patent_app_date] => 2018-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 8 [patent_no_of_words] => 4817 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15913550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12908980 [patent_doc_number] => 20180194835 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => USE OF VEGF ANTAGONIST IN TREATING CHORIORETINAL NEOVASCULAR AND PERMEABILITY DISORDERS IN PAEDIATRIC PATIENTS [patent_app_type] => utility [patent_app_number] => 15/906421 [patent_app_country] => US [patent_app_date] => 2018-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13114 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15906421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18152022 [patent_doc_number] => 11564972 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-31 [patent_title] => Methods of using compositions comprising variants of FGF19 polypeptides for treating primary biliary cirrhosis in a subject [patent_app_type] => utility [patent_app_number] => 15/895812 [patent_app_country] => US [patent_app_date] => 2018-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 33911 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15895812 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13342841 [patent_doc_number] => 20180222960 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/891492 [patent_app_country] => US [patent_app_date] => 2018-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44750 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15891492 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12837508 [patent_doc_number] => 20180171009 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => M-CSF Specific Monoclonal Antibody and Uses Thereof [patent_app_type] => utility [patent_app_number] => 15/891051 [patent_app_country] => US [patent_app_date] => 2018-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46021 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -155 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15891051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13368989 [patent_doc_number] => 20180236035 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => PROTEIN THERAPY FOR TREATMENT OF RETINAL DISEASES [patent_app_type] => utility [patent_app_number] => 15/889252 [patent_app_country] => US [patent_app_date] => 2018-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37671 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15889252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13342887 [patent_doc_number] => 20180222983 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => METHODS, COMPOSITIONS, AND KITS FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 15/890278 [patent_app_country] => US [patent_app_date] => 2018-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7016 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15890278 [rel_patent_id] =>[rel_patent_doc_number] =>)